Gemina Laboratories Ltd
CNSX:GLAB
Gemina Laboratories Ltd
Gemina Laboratories Ltd. (Gemina) is a Canada-based biotechnology company. Gemina operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. It is engaged in biosensor and diagnostic services with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Gemina's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Gemina is focused on infectious respiratory diseases and the recovery from them. It has developed a first-generation technology (the Generation 1 Technology), which it has included within an initial demonstration product namely: a point-of-care lateral flow assay to test whether a person is infected with COVID-19 (the Legio-XTM COVID Rapid Antigen Test).
Gemina Laboratories Ltd. (Gemina) is a Canada-based biotechnology company. Gemina operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. It is engaged in biosensor and diagnostic services with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Gemina's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Gemina is focused on infectious respiratory diseases and the recovery from them. It has developed a first-generation technology (the Generation 1 Technology), which it has included within an initial demonstration product namely: a point-of-care lateral flow assay to test whether a person is infected with COVID-19 (the Legio-XTM COVID Rapid Antigen Test).
